Abstract
The TWEAK/Fn14 pathway is now well-known for its involvement in the modulation of inflammation in various human autoimmune/chronic inflammatory diseases (AICID) including lupus, rheumatoid arthritis, and multiple sclerosis. A panel of data is now available concerning TWEAK expression in tissues or biological fluids of patients suffering from AICID, suggesting that it could be a promising biological marker in these diseases. Evidences from several teams support the hypothesis that blocking TWEAK/Fn14 pathway is an attractive new therapeutic lead in such diseases and clinical trials with anti-TWEAK-blocking antibodies are in progress. In this mini-review we discuss the potential use of TWEAK quantification in AICD management in routine practice and highlight the challenge of standardizing data collection to better estimate the clinical utility of such a biological parameter.
Introduction
Autoimmune and chronic inflammatory diseases (AICID) including rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE), or systemic sclerosis (SSc) constitute an important medical, social, and economic problem. The prevalence of AICID is estimated to be more than 3% in the adult population () and despite scientific progress in the past decade, identification of new reliable markers for diagnosis, prognosis, and prevention of hospitalization is still necessary.
TWEAK is a pleiotropic and multifunctional cytokine that regulates inflammatory pathways by inducing multiple cellular responses depending on the cell type and its micro-environment. During tissue repair and remodeling, the biological activity of TWEAK is complex and even dual: after acute injury, TWEAK promotes tissue regeneration especially by stimulating progenitor cells, but in chronic diseases where TWEAK is persistently activated, it alters tissue repair in part by inhibiting differentiation of the same progenitor cells (). A growing body of data points to the involvement of the TWEAK/Fn14 pathway in inflammation in various human AICID including SLE, RA, and MS. It is now admitted that TWEAK plays a role in the physiopathology of such diseases and the first clinical trials are in progress, based on anti-TWEAK-blocking therapies during RA or SLE (, ). Nevertheless it remains to be proven that the assessment of TWEAK levels in tissues or biological fluids is of interest for the management of patients suffering from AICID. In this article we propose to review the available data on TWEAK quantification in human AICID and to discuss the potential place and the modalities of TWEAK evaluation in the diagnosis and/or the follow-up of AICID.
TWEAK Evaluation in AICID: Why, When, and What for?
Biomarkers in medicine have gained immense scientific and clinical interest in recent years. Biomarkers are potentially useful in the context of primary, secondary, and tertiary prevention. An ideal biomarker should be safe to assess, easy to measure and associated with acceptable costs. Additionally, the biomarker should have “good performance characteristics” (i.e., sensitivity, specificity, positive- and negative-predictive values) and there should be scientific evidence to suggest that biomarker modification influences disease outcome.
In AICID, various serum circulating auto-antibodies are widely used as reliable markers for diagnostic or sometimes prognostic evaluation. Nevertheless the identification of new markers to evaluate inflammatory activity of the disease, to predict disease flare or to monitor the clinical response to biotherapy remains necessary.
The idea that TWEAK could be such a biomarker in AICID is suggested by its role in the modulation of inflammation in AICID both in animal models and in human pathologies. Moreover, in the past decade, various research groups have shown modulation of TWEAK expression in tissue and biological fluids of patients suffering from AICID.
For establishing a diagnosis of AICID
Very few data are available concerning the diagnostic potential of soluble TWEAK in AICID. Among them, urinary TWEAK (uTWEAK) has been proposed by Schwartz and colleagues as a biomarker for lupus nephritis (LN) as they showed that it is elevated in subjects with LN at diagnosis compared with those with SLE but no renal disease (). Moreover uTWEAK levels were better at distinguishing LN and non LN-SLE than anti-DNA antibodies and complement levels. Schwartz et al. also reported that serum TWEAK (sTWEAK) levels and the urine/sTWEAK ratio were not better markers for LN than the less invasive uTWEAK. It is intriguing to note in this work that sTWEAK levels were significantly lower in SLE patients than in healthy individuals. Later, El-Shehaby et al. have also shown that uTWEAK levels positively correlate with renal involvement during SLE with a positive predictive value of the marker of 93% for kidney inflammation ().
For following-up disease activity
Autoimmune and chronic inflammatory diseases are chronic diseases that usually fluctuate between periods of remission (little/no symptoms) and unpredictable flare-ups (worsening symptoms). In this context, the ability to predict the severity of disease and the outcome of flares should allow tertiary prevention of disease complications. In LN, renal biopsy remains the gold standard for assessment of disease activity but because of its invasive modalities, this approach cannot be used repeatedly in clinical practice to follow-up disease activity. In this context, uTWEAK has been shown to correlate with the degree of clinical disease activity during LN () and fluctuations of uTWEAK levels were found to reflect LN flares. uTWEAK could thus represent an interesting biological tool if the diagnosis of a flare is in doubt.
In RA, auto-immunity and chronic inflammation leads to the destruction of cartilage and bone in the joints. The relationship between TWEAK and arthritis has been supported by anti-inflammatory and anti-angiogenic effects of TWEAK inhibition in a mouse model of collagen-induced arthritis (, ). Park et al. showed for the first time that sTWEAK levels were higher in RA patients than in healthy controls (). Moreover, sTWEAK levels in RA patients positively correlated with the DAS 28 disease activity scores ().
In 2009, Yanaba et al. described for the first time elevated sTWEAK levels in patients suffering from another AICID, SSc, a generalized connective tissue disorder characterized by sclerotic changes in the skin and internal organs. The longitudinal study of sTWEAK levels performed in this study showed that these high soluble TWEAK levels were associated with a lower prevalence of pulmonary fibrosis and better pulmonary function in SSc patients. This perturbed expression of TWEAK suggested some involvement of the TWEAK pathway in the appearance of pulmonary fibrosis, a well-known complication of the disease. Nevertheless the mechanisms and the meaning of the elevation of sTWEAK levels in this context remain to be determined ().
For monitoring therapies targeting TNF superfamily members
Currently, few autoimmune diseases can be cured with treatment. In the last decade, TNF blocking agents have been developed for the treatment of human diseases and have been very successful in ameliorating disease signs and symptoms especially in patients suffering from AICID like RA.
According to the work of Park et al. high sTWEAK levels have been shown to correlate with TNF alpha levels in RA patients and to reflect short-term response to etanercept, a biotherapy targeting TNF alpha (). In fact, responders to etanercept showed a significant decrease in sTWEAK levels at the 12th week of treatment, whereas TWEAK levels in non-responders were not different from their baseline levels. TWEAK is a member of TNF family. Like TNF inhibition, TWEAK inhibition is an attractive therapeutic option in AICID. The results of the first study exploring the safety and tolerability (phase I) of a TWEAK-blocking therapy using the monoclonal antibody BIIB023 in patients with RA have been recently published (). They demonstrated that a single-dose administration of BIIB023 was well tolerated in patients with RA and was associated with a suppression of sTWEAK levels for up to 28 days in the case of BIIB023 high dose. The efficacy of BIIB023 (phase II) is now explored in the ongoing clinical trial ATLAS (Anti-TWEAK in Lupus Nephritis patients) for patients with lupus nephritis, a pathology that requires a more innovative treatment than RA. In this context, quantification of soluble TWEAK in anti-TWEAK treated patients is an interesting way for managing BIIB023 administration.
TWEAK Evaluation in AICID: How to Proceed?
Which form of TWEAK to quantify: membrane and/or soluble form?
TWEAK expression has been studied in various AICID animal models and in humans (–). The main cellular sources of TWEAK are cells from the monocyte/macrophage family including immune infiltrating cells in tissues during inflammation. TWEAK can expressed as a type II transmembrane protein or efficiently cleaved to generate sTWEAK. Elevated levels of sTWEAK can be found locally at the site of diseased tissue during AICID. The presence of membrane-bound TWEAK has also been described in human cells (–) but not in other studies of freshly isolated peripheral blood mononuclear cells (PBMCs) from normal subjects or patients with RA or SLE (Linda Burkly, personal communication). Nevertheless the relevance of one form versus the other is not yet elucidated. Modulation of the soluble form levels rather than the membrane form is more frequently studied and published.
Which sample to collect and to use for TWEAK quantification?
Soluble TWEAK is currently quantified in patient serum due to the facility of routine blood collection by venous puncture. But depending on the target tissue involved in AICID soluble TWEAK could be quantified in various other body fluids such as synovial fluid (), cerebrospinal fluid (), or urine () and may better reflect inflammatory activity in respectively the joint, the brain, and the kidney. TWEAK expression during AICID has also been studied in PBMCs by western blot and PCR. In SLE, elevation of TWEAK in PBMC is correlated with disease activity and lupus nephritis (). In SSc, the production of soluble TWEAK by cultured PBMC is significantly diminished in patients with more severe microvascular damage as indicated by capillaroscopy (). In the context of neuroinflammation, Serafini et al. reported strong TWEAK expression on post-mortem MS brain tissue while TWEAK was generally undetectable by immunohistochemistry in the normal human brain white matter or cerebral cortex samples (). Even if these results are very interesting for further evaluation of the role of TWEAK in MS physiopathology, these approaches are not appropriate for routine diagnosis of MS. Desplat-Jégo et al. have shown by using PBMC analysis after culture that TWEAK is expressed at the cell surface of circulating monocytes during MS and not during non-MS neurological inflammatory diseases (). This study also showed that TWEAK was detectable in the serum and CSF of MS patients but found no significant difference between the MS group and other clinical groups.
In RA, data on TWEAK/Fn14 expression in the synovium of patients are available (, ) and support a high level of TWEAK in RA synovial tissue concordant with the numerous activated macrophages found in synovium during the disease and with the beneficial effect of TWEAK blockade in a mouse model of RA.
To quantify TWEAK alone or associated with other(s) biological parameter(s)?
Panel-based approaches measuring a combination of biological parameters are more and more used for routine biological diagnosis of human diseases. Very few studies have addressed the diagnostic performance of associating TWEAK with one or several other markers.
Moreno et al. have reported that soluble CD163/soluble TWEAK ratio in peripheral blood is a more sensitive biomarker of subclinical atherosclerosis than soluble CD163 or soluble TWEAK alone (). CD163 is a member of the scavenger receptor cysteine-rich family now recognized as an immunomodulator of the atherosclerotic plaque. It has been previously proposed that TWEAK could specifically bind and neutralize TWEAK and that CD163-expressing monocytes/macrophages were able to bind and internalize exogenous TWEAK (). However this interaction has recently failed to be confirmed (). Nonetheless, Kowal-Bielecka et al. have recently shown that a high serum soluble CD163/soluble TWEAK ratio is associated with lower risk of digital ulcers but with a more severe skin disease in patients with SSc ().
In the case of spot urine exploration of soluble TWEAK, it is recommended to normalize TWEAK levels to urinary creatinine measured in the same spot urine since creatinine excretion rate into the urine is relatively constant and allows to compensate for the variability in the volume of urine and the concentrations of soluble TWEAK from void to void ().
TWEAK Evaluation in AICID: How to Define Pathological Values?
In the first place, normal value ranges have to be determined prior to the definition of pathological values for sTWEAK levels in humans. A threshold for pathological TWEAK levels has to be established. It is not an easy task. Different ranges of normal values issued from various laboratory teams are available (Table 1) and there is obviously a lack of homogeneity. The differences observed in soluble TWEAK levels in healthy control subjects depend presumably on various parameters: age, sex, ethnic origin of the recruited control group, pre-analytical conditions especially sample storage conditions before analysis, the technical characteristics of the ELISA kits, nature of TWEAK epitopes recognized by anti-TWEAK antibodies, capacity of soluble TWEAK to trimerize etc. Table 1 summarizes the data obtained by 10 teams and shows the difficulty in obtaining to date consensual normal values for sTWEAK levels.
Table 1
| Publication reference | ELISA kit manufacturer | Number of control healthy subjects tested | Serum soluble TWEAK levels (pg/ml) Mean ± SD (ranges) |
|---|---|---|---|
| Park et al. () | Bender Medsystems | 40 | 42.7 ± 14.5 |
| Yanaba et al. () | Bender Medsystems | 31 | 41.5 ± 33.5 |
| Yilmaz et al. () | Bender Medsystems | 55 | 445 (326–634) |
| Chorianopoulos et al. () | Bender Medsystems | 30 | 377 (310–432) |
| Xia et al. () | Bender Medsystems | 45 | 34.8 (15–54) |
| Kowal-Bielecka et al. () | Bender Medsystems | 48 | 294 ± 147 (132–1015) |
| Turkmen et al. () | Bender Medsystems | 25 | 457 (320–538) |
| Desplat-Jégo, personal results | Bender Medsystems | 58 | 467 (200–866) |
| Schwartz et al. () | Home-made ELISA | 19 | 23.5 (17.3–27.1) |
| Llaurado et al. () | R&D Systems | 68 | 1636 (1146–3754) for men and 1401 (788–2422) for women |
“Normal” mean values and ranges for serum soluble TWEAK in humans determined by ELISA.
SD, standard deviation.
In urine, LN patients have been compared with control subjects but data obtained in this latter group was detailed by only one team in 23 healthy volunteers with a reference value for uTWEAK of 5.67 pg/mg of creatinine (interquartile range: 3.10) (, , ).
In the case of other biological fluids (CSF, synovial fluid) data are lacking to establish normal ranges especially because collections of such fluids are invasive and not allowed in control healthy subjects by ethic committees.
In Conclusion
On the one hand, quantification of uTWEAK in AICID seems to be an interesting tool in the follow-up of disease activity especially in lupus nephritis. On the other hand it is premature to propose sTWEAK as a diagnostic tool of AICID due to the lack of specificity for one disease in particular. Moreover studies analyzing diagnostic performance of serum sTWEAK are still needed. sTWEAK assay is nevertheless useful in the follow-up of anti-TWEAK biotherapies and perhaps could be useful in the follow-up of anti-TNFα therapies but this latter point needs to further be evaluated. At this point, the most important criticism concerning TWEAK evaluation in AICID is the difficulty in obtaining consensual ranges for normal values of sTWEAK. Reagents for the assessment of TWEAK levels are now commercially available for research purposes only. However, standardization of the proposed kits is absolutely required all the more because free soluble TWEAK is a “sticky” protein difficult to manipulate based on experience from our team and others (). Moreover comparison between studies using different reagents must be conducted carefully. It is our opinion that the standardization of data collection is critical to further evaluate the clinical utility of TWEAK as a promising biomarker.
Statements
Acknowledgments
This work was supported in part by a grant research from the Agence Nationale de la Recherche (ANR-09-MNPS-030) (to Sophie Desplat-Jégo).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
CooperGSBynumMLKSomersEC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun (2009) 33(3–4):197–207.10.1016/j.jaut.2009.09.008
2
BurklyLCMichaelsonJSHahmKJakubowskiAZhengTS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine (2007) 40(1):1–16.10.1016/j.cyto.2007.09.007
3
WisniackiNAmaravadiLGalluppiGRZhengTSZhangRKongJet alSafety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther (2013) 35(8):1137–49.10.1016/j.clinthera.2013.06.008
4
ATLAS. Anti-TWEAK in Lupus Nephritis Patients. Clinical Trials.gov (2013). Available from: http://clinicaltrials.gov/ct2/show/NCT01499355?term=BIIB023&rank=3
5
SchwartzNRubinsteinTBurklyLCCollinsCEBlancoISuLet alUrinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther (2009) 11(5):R143.10.1186/ar2816
6
El-ShehabyADarweeshHEl-KhatibMMomtazMMarzoukSEl-ShaarawyNet alCorrelations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol (2011) 31(5):848–56.10.1007/s10875-011-9555-1
7
PerperSJBrowningBBurklyLCWengSGaoCGizaKet alTWEAK is a novel arthritogenic mediator. J Immunol (2006) 177(4):2610–20.
8
KamataKKamijoSNakajimaAKoyanagiAKurosawaHYagitaHet alInvolvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol (2006) 177(9):6433–9.
9
ParkM-CChungSJJungS-JParkY-BLeeS-K. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol (2008) 37(3):173–8.10.1080/03009740801898608
10
YanabaKYoshizakiAMuroiEHaraTOgawaFUsuiAet alElevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol (2009) 36(8):1657–62.10.3899/jrheum.081310
11
SerafiniBMagliozziRRosicarelliBReynoldsRZhengTSAloisiF. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J Neuropathol Exp Neurol (2008) 67(12):1137–48.10.1097/NEN.0b013e31818dab90
12
Van KuijkAWRWijbrandtsCAVinkenoogMZhengTSReedquistKATakPP. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis (2010) 69(1):301–4.10.1136/ard.2008.090548
13
Desplat-JégoSVarrialeSCreidyRTerraRBernardDKhrestchatiskyMet alTWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol (2002) 133(1–2):116–23.10.1016/S0165-5728(02)00368-5
14
Desplat-JégoSCreidyRVarrialeSAllaireNLuoYBernardDet alAnti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol (2005) 117(1):15–23.10.1016/j.clim.2005.06.005
15
NakayamaMKayagakiNYamaguchiNOkumuraKYagitaH. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med (2000) 192(9):1373–80.10.1084/jem.192.9.1373
16
KaplanMJRayDMoRRYungRLRichardsonBC. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol (2000) 164(6):2897–904.
17
Desplat-JégoSFeuilletLCreidyRMalikovaIRanceRKhrestchatiskyMet alTWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol (2009) 85(1):132–5.10.1189/jlb.0608347
18
DharmapatniAASSKSmithMDCrottiTNHoldingCAVincentCWeedonHMet alTWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther (2011) 13(2):R51.10.1186/ar3294
19
SchwartzNSuLBurklyLCMackayMAranowCKollarosMet alUrinary TWEAK and the activity of lupus nephritis. J Autoimmun (2006) 27(4):242–50.10.1016/j.jaut.2006.12.003
20
LiuZ-CZhouQ-LLiX-ZYangJ-HAoXVeeraragooPet alElevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine (2011) 53(3):295–300.10.1016/j.cyto.2010.11.012
21
BieleckiMKowalKLapinskaAChwieckoJSkowronskiJSierakowskiSet alDiminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol (2009) 47(3):465–9.10.2478/v10042-009-0103-2
22
MorenoJAMuñoz-GarcíaBMartín-VenturaJLMadrigal-MatuteJOrbeJPáramoJAet alThe CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 207(1):103–10.10.1016/j.atherosclerosis.2009.04.033
23
BoverLCCardó-VilaMKuniyasuASunJRangelRTakeyaMet alA previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 178(12):8183–94.
24
FickALangISchäferVSeherATrebingJWeisenbergerDet alStudies of binding of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem (2012) 287(1):484–95.10.1074/jbc.M111.287656
25
Kowal-BieleckaOBieleckiMGuiducciSTrzcinska-ButkiewiczBMichalska-JakubusMMatucci-CerinicMet alHigh serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther (2013) 15(3):R69.10.1186/ar4246
26
YilmazMICarreroJJOrtizAMartin-VenturaJLSonmezASaglamMet alSoluble TWEAK plamsa levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 4(11):1716–23.10.2215/CJN.02760409
27
ChorianopoulosEJarrKSteenHGiannitsisEFreyNKatusHA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis (2010) 211:322–6.10.1016/j.atherosclerosis.2010.02.016
28
XiaLShenHXiaoWLuJ. Increased serum TWEAK levels in psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine (2011) 53(3):289–91.10.1016/j.cyto.2010.12.003
29
TurmenKTonbulHZErdurFMTokerABiyikZOzbinerHet alSoluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol (2013) 14:144.10.1186/1471-2369-14-144
30
LlauradoGGonzalez-ClementeJMMaymo-MassipESubiasDVendrellJChaconMR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors: a case-control study. PLoS One (2012) 7(8):e43919.10.1371/journal.pone.0043919
31
LammensABaehnerMKohnertUNiewoehnerJvon ProffLSchraemlMet alCrystal structure of human TWEAK in complex with the Fab fragment of a neutralizing antibody reveals insights into receptor binding. PLoS One (2013) 8(5):e62697.10.1371/journal.pone.0062697
Summary
Keywords
TWEAK, biomarker, auto-immunity, disease monitoring, serum levels, urinary levels
Citation
Bertin D, Stephan D, Khrestchatisky M and Desplat-Jégo S (2013) Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?. Front. Immunol. 4:489. doi: 10.3389/fimmu.2013.00489
Received
30 October 2013
Accepted
13 December 2013
Published
27 December 2013
Volume
4 - 2013
Edited by
Linda C. Burkly, Biogen Idec, Inc., USA
Reviewed by
Massimo Gadina, National Institutes of Health, USA; Meena Subramanyam, Biogen Idec, Inc., USA
Copyright
© 2013 Bertin, Stephan, Khrestchatisky and Desplat-Jégo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sophie Desplat-Jégo, Service d’Immunologie, Pôle de Biologie, Hôpital de la Conception, Assistance Publique – Hôpitaux de Marseille, 147 Bd Baille, 13005 Marseille, France e-mail: sophie.jego-desplat@ap-hm.fr
This article was submitted to Inflammation, a section of the journal Frontiers in Immunology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.